Article

AMO buys VISX

The unexpected move by Advanced Medical Optics Inc. (AMO) to acquire VISX Inc. in a $1.27 billion cash and stock deal caught Wall Street-and many in the ophthalmic industry-by complete surprise.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
Related Content
Lupin launches loteprednol etabonate ophthalmic suspension, 0.5%, in the United States
July 19th 2025

Lupin launches loteprednol etabonate ophthalmic suspension, 0.5%, in the United States

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Children with ADHD may be less likely to develop myopia, study suggests
July 18th 2025

Children with ADHD may be less likely to develop myopia, study suggests

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

AAVantgarde Bio receives IND clearance for AAVB-039
July 17th 2025

AAVantgarde Bio receives IND clearance for AAVB-039

FDA accepts for review Aldeyra Therapeutics’ resubmitted New Drug Application for reproxalap
July 17th 2025

FDA accepts for review Aldeyra Therapeutics’ resubmitted New Drug Application for reproxalap

© 2025 MJH Life Sciences

All rights reserved.